AcelRx Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Co.'s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. Co.'s nafamostat product candidates include Niyad™, which is being developed as a regional anticoagulant for injection into the extracorporeal circuit; and LTX-608, which is Co.'s proprietary nafamostat formulation for direct IV infusion. Co.'s pre-filled syringe product candidates include Fedsyra™, which is an ephedrine pre-filled syringe; and the phenylephrine pre-filled syringe. We show 2 historical shares outstanding datapoints in our TLPH shares outstanding history coverage, used to compute TLPH market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing TLPH market cap history over the course of time is important for investors
interested in comparing TLPH's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of TLPH versus a peer is one thing; comparing
TLPH market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like TLPH can fluctuate over the course of history.
With this page we aim to empower investors researching TLPH by allowing them to research the TLPH market cap history. |
Free TLPH Email Alerts:
Video: The Importance of Market Cap
